CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...
A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...
The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
Laura Huppert, MD, discusses efficacy and safety outcomes from the phase 3 ASCENT-04 trial, which compared the combination of ...
The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...
During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.
The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...
Recent studies highlight the effectiveness of lenvatinib and pembrolizumab in improving overall survival for patients with ...
Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with ...
A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...
Ramez N. Eskander, MD, discusses the heterogenous nature of endometrial cancer and molecular testing being used to identify appropriate patients for specific treatments. He also highlights what study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback